Predicting lithium treatment response in bipolar patients using gender-specific gene expression biomarkers and machine learning [version 1; peer review: 1 approved with reservations]

Andy R. Eugene1, Jolanta Masiak2, Beata Eugene3

1Department of Pharmacogenomics, Bernard J. Dunn School of Pharmacy, Inova Center for Personalized Health, Shenandoah University, Fairfax, VA, 22031, USA
2Independent Neurophysiology Laboratory, Department of Psychiatry, Medical University of Lublin, Lublin, 20-439, Poland
3Marie-Curie Sklodowska University, Lublin, 20-400, Poland

Abstract

Background: We sought to test the hypothesis that transcriptome-level gene signatures are differentially expressed between male and female bipolar patients, prior to lithium treatment, in a patient cohort who later were clinically classified as lithium treatment responders.

Methods: Gene expression study data was obtained from the Lithium Treatment-Moderate dose Use Study data accessed from the National Center for Biotechnology Information’s Gene Expression Omnibus via accession number GSE4548. Differential gene expression analysis was conducted using the Linear Models for Microarray and RNA-Seq (limma) package and the Random Forests machine learning algorithm in R.

Results: In pre-treatment lithium responders, the following genes were found having a greater than 0.5 fold-change, and differentially expressed indicating a male bias: RBPMS2, SIDT2, CDH23, LILRA5, and KIR2DS5; while the female-biased genes were: HLA-H, RPS23, FHL3, RPL10A, NBPF14, PSTPIP2, FAM117B, CHST7, and ABRACL.

Conclusions: Using machine learning, we developed a pre-treatment gender- and gene-expression-based predictive model selective for lithium responders with an ROC AUC of 0.92 for men and an ROC AUC of 1 for women.

Keywords

lithium, treatment response, gene expression, machine learning, microarray, transcriptome, precision medicine, pharmacogenomics
Corresponding author: Andy R. Eugene (andyeugene.md@gmail.com)

Author roles: Eugene AR: Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Project Administration, Resources, Software, Supervision, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; Masiak J: Project Administration, Writing – Review & Editing; Eugene B: Formal Analysis, Investigation, Methodology, Project Administration, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2018 Eugene AR et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Eugene AR, Masiak J and Eugene B. Predicting lithium treatment response in bipolar patients using gender-specific gene expression biomarkers and machine learning [version 1; peer review: 1 approved with reservations]
F1000Research 2018, 7:474 https://doi.org/10.12688/f1000research.14451.1

First published: 18 Apr 2018, 7:474 https://doi.org/10.12688/f1000research.14451.1
Introduction

Lithium is the most well-established mood-stabilizer in the practice of psychiatry (Jermain et al., 1991; Landersdorfer et al., 2017). A recent propensity-score adjusted and matched longitudinal cohort-study evaluating the effectiveness of the newer mood stabilizers: olanzapine (n=1477), quetiapine (n=1376), and valproate (n=1670), in comparison to lithium (n=2148), found that patients treated with lithium experienced reduced rates of both unintentional injury and self-harm (Hayes et al., 2016). However, due to lithium’s narrow window, 0.5-1.2 mEq/mL, of maximal effectiveness and safety (i.e. therapeutic index), Therapeutic Drug Monitoring is the standard-of-care to ensure patient safety in medical practice (Hiemke et al., 2011). Further, divergent clinical response rates have been reported among male and female patients diagnosed with bipolar disorder and treated with lithium (Viguera et al., 2000).

In a 1986, Zetin and colleagues published the results of a study that evaluated four methods for predicting lithium daily dosages, and the final equation resulted in a 147.8mg/day increased dosage-adjustment for male patients (Zetin et al., 1986). Similarly, a later study by Lobeck and colleagues corroborated the 147.8 mg/day male increase dose requirement for the lithium maintenance dose in bipolar patients (Lobeck et al., 1987). However, neither do the current dosing guidelines recommend a gender-based dose adjustment via clinical pharmacometrics, to avoid toxicity, nor are gender-specific gene expression screening panels available to predict lithium efficacy currently available and implemented.

A recent large-scale meta-analysis of human body-tissue gene expression reported that the body organ with the most abundant gender-biased gene expression is the anterior cingulate cortex within the frontal cortex of the brain (Mayne et al., 2016). Thus, these findings suggest that therapeutic drug response may be influenced not only via drug absorption, distribution, metabolism, and elimination, but also within the underlying gene signatures across the human transcriptome and mechanisms of gene-gene interactions that regulate physiology. Beech and colleagues conducted a study to identify gene expression differences from the peripheral blood in patients classified as lithium responders and non-responders (Beech et al., 2014). However, the study reported that no significant gender-biased gene expression differences were found (p-value=0.941) in patients who were randomized to optimal therapy (control), defined as one FDA-approved mood stabilizer, versus patients treated with lithium plus optimal therapy (Beech et al., 2014). Despite these initially reported findings, a recent study by Labonté and colleagues, which used RNA-Seq to evaluate the transcriptome in patients diagnosed with major depressive disorder (MDD), concluded that gender dimorphism exists at the transcriptome-level in MDD patients and that gender-specific treatments should be investigated (Labonté et al., 2017).

Therefore, there is an urgent clinical need to improve behavioral healthcare by understanding gene expression variability that may lead to personalizing medicine in patients with mania. These findings may improve prediction of clinical drug response of lithium prior to initiating pharmacotherapy in patients with bipolar or schizoaffective disorders, who cannot risk drug inefficacy for obvious safety reasons. Therefore, the overall aim for our study is to define gender-specific transcriptional-level regulators of lithium treatment response that may influence treatment of bipolar or schizoaffective disorders. We will test the hypothesis that biologically plausible gene expression differences exist, prior to lithium treatment, in patients diagnosed with bipolar disorder in the following three patient subgroups: (1) male and female patients who were later clinically classified as lithium treatment responders; (2) male-responders versus male-non-responders; (3) female-responders versus female-non-responders.

Methods

Data

DNA microarray data analyzed in this study are originally referenced from the Lithium Treatment-Moderate dose Use Study placed in the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO) via accession number GSE45484 with the Illumina HumanHT12 V4.0 expression Beadchip GPL10558 platform file to associate gene names and descriptions. The original multisite clinical study recruited patients from Case Western Reserve University, Massachusetts General Hospital, Stanford University, Yale University, and the Universities of: Pittsburgh, Texas Health Science Center at San Antonio, and Pennsylvania (Beech et al., 2014). From the original 120 peripheral blood samples used to generate probe and gene expression profiles, from patients diagnosed with bipolar disorder, the clinical phenotype of being either a treatment- responder or non-responder was assessed using the Clinical Global Impression Scale for Bipolar Disorder-Severity (CGI-BP-S) (Spearing et al., 1997).

Study design

To assess for gender-specific differential gene signatures, in our first analysis we grouped patients based on gender alone and not on any other variables (i.e. optimal treatment versus lithium, or responder versus non-responder status). From the results of the gender-specific transcriptome signatures in first analysis, we set the top two-hundred and fifty genes as controls that would be excluded from all results that would be reported in subsequent gene expression analyses to identify genes with lithium-specific gene expression differences between genders associated with response to lithium treatment. In our second analysis, we only selected patients who were classified as lithium treatment-responders, at baseline, and the results from the gene expression differences are reported excluding the sex-specific control genes identified in the first experiment. In our third and fourth analyses, we compared: male-responders vs. male non-responders, and female-responders vs. female non-responders, respectively.

Gene expression analysis

Differential gene expression analysis of the microarray data was conducted using the Empirical Bayes method implemented within the limma package (version 3.34.5) and utilizes the Biobase package (version 2.38.0) which both run within the R for Statistical Programming environment (version 3.4.3; R Foundation for Statistical Computing, Vienna, Austria) (Ritchie et al., 2015; Team, 2013). Due to multiple testing of the peripheral blood transcriptome, the False-Discovery Rate was adjusted using the Benjamini-Hochberg method. The Decision Tree and Random
Forests machine learning algorithms were used to assess gender using transcriptional signatures and for predictive modeling using the discovered microarray genes to select for the gender-specific lithium responders. A p-value of less 0.05 was considered to be statistically significant and a differential gene expression threshold of 0.5 was used and reported during the machine learning process. Further methods detailing the Random Forests decision processes for male- and female-responders are located in Supplementary File 1.

Results Table 1 provides the patient age and sample sizes used during subgroup analyses. In our first analysis, which aimed to group patients based on gender alone and not based on clinical variables detailed in the original study, data-driven gene analytics identified four female-labeled patient samples with gene expression levels similar to that found in male patients for the following Y-chromosome genes: RPS4Y1, EIF1AY, KDM5D, RPS4Y2; and the XIST gene located on the X-chromosome. Therefore, all subsequent hypothesis-testing were analyzed with the updated male-gender classification for the following NCBI GEO patient samples: GSM1105526 (baseline lithium-non-responder), GSM1105528 (1-month lithium-non-responder), GSM1105546 (baseline lithium-non-responder), and GSM1105548 (1-month lithium-non-responder). Figure 1 illustrates the gene expression findings resulting in re-assignment for the aforementioned patient samples from females to males using a decision-tree approach that evaluated if the RPS4Y1 gene had an expression level of greater than or equal to 9.6 resulting in: yes=male (31%) and no=female (69%). After proceeding with the machine learning analysis of both the ‘training’ and ‘validation’ datasets, the final ‘test’ dataset resulted in the following diagnostic test evaluation parameters: Sensitivity=100% (95% C.I. 66.37%-100.00%), Specificity=100% (95% C.I. 78.20%-100.00%), and an area under the receiver operator characteristic (ROC) curve of 1. Figure 2 illustrates the variable importance plots used in the machine learning process.

Table 2 provides the results for the gender-specific differentially expressed genes from the entire study population using a fold-change (FC) threshold of 0.5. A total of five genes met the a priori FC requirements and were found to be RPS4Y1, EIF1AY, KDM5D, RPS4Y2, and EIF1AY. These five down-regulated male-biased genes were all found on the Y-chromosome. Contrarily, a total of 10 upregulated female-biased genes were found to be: XIST, S100P, IFIT3, TNFAIP6, IFITM3, IFIT2, CHURC1, ANXA3, ADM, and PROK2. The RPS4Y1 gene in males (FC=-4.9807, p=7.36E-47) and the XIST gene (FC=1.7615, p=2.98E-36), found

### Table 1. Patient age and sample sizes used during subgroup analyses.

| Lithium treated patient population | Baseline | Mean age | S.D. | Sample size (n) |
|-----------------------------------|----------|----------|------|-----------------|
| Male-responder                    | 36       | 8.1      | 3    |                 |
| Female-responder                  | 31       | 11.8     | 6    |                 |
| Male-non-responder                | 40       | 10       | 7    |                 |
| Female-non-responder              | 44       | 9.2      | 12   |                 |

| General mood stabilizers patient population | Baseline | Mean age | S.D. | Sample size (n) |
|---------------------------------------------|----------|----------|------|-----------------|
| Male-responder                              | 51       | --       | 1    |                 |
| Female-responder                            | 49       | 10.5     | 3    |                 |
| Male-non-responder                          | 43       | 12.5     | 9    |                 |
| Female-non-responder                        | 37       | 14.5     | 19   |                 |

| Total patient population | Gender | Mean age | S.D. | Sample size (n) |
|--------------------------|--------|----------|------|-----------------|
| Male                     | 41     | 10.8     | 20   |                 |
| Female                   | 39     | 13.1     | 40   |                 |
| Study population         | 40     | 12.3     | 60   |                 |

*Note: United States Food and Drug Administration approved Mood Stabilizers.

**Figure 1.** Gene expression levels for the Ribosomal protein S4, Y-linked 1 (RPS4Y1) gene illustrating 4 patient samples as labeled as female and were re-assigned to the male patient gender group. Males (n=41) and Females (n=39).
Figure 2. Variable importance ratings of genes selective (above) male lithium responders versus the entire population of treated and untreated patient men and women; and (below) female lithium responders versus the entire population of treated and untreated men and women.
on the X-chromosome, in females resulted in the greatest expression changes between genders. The male-favored genes resulted in a larger expression change than compared to the females.

Table 3 provides the results for the differentially expressed genes that were found between male and female responders prior to initiation of lithium and optimal therapy, meeting the FC criteria of at least 0.5. In male lithium responders, we found 5 differentially expressed and down-regulated genes while the RNA binding protein with multiple splicing 2 (RBPMS2) gene ranked with the greatest FC of -1.351 (unadjusted p=0.00111). Whereas, 9 up-regulated genes were associated with female lithium responders, with greatest expression change being the major histocompatibility complex class-1-H (HLA-H) at 1.602 (unadjusted p-value=0.00099). The neuroblastoma breakpoint family member-14 (NBPF14) gene met the Benjamani-Hochberg adjusted p-value criteria and resulted with an expression change of 0.586 (adjusted p=0.0462). Figure 3 illustrates the heat-map and dendrogram overview of the two-way unsupervised hierarchical cluster analysis of the reported differentially expressed genes among male and female responders to lithium therapy at baseline that correspond to values reported in Table 3.

Using the baseline blood sample microarray data, the predictive modeling results for identifying lithium-responders from the complete study population of male and female controls and treatment samples, resulted in a validation/test sample cohort for males of: Sensitivity=95.83% (95% C.I. 78.88%-99.89%), Specificity= not calculated due sample size of test dataset, and an ROC curve AUC = 0.92 using the RBPMS2 and LILRA5 genes. Likewise, in the test dataset for females: Sensitivity=91.67% (95% C.I. 61.52%-99.79%), Specificity= not calculated due sample size of test dataset, and an ROC curve AUC = 1 with the ABRACL and NBPF14 genes. Therefore, we developed a 2-gene predictive model for men and likewise for women predicting lithium response in bipolar patients from a general population of bipolar patients using transcriptional signatures at baseline.

Table 4 provides the list of 10 differentially expressed genes found in male lithium responders (5-genes) and male lithium-non-responders (5-genes). The RNA binding protein with multiple splicing 2 (RBPMS2) gene (FC= -1.326, unadjusted p=0.001358) in male lithium responders and the Ribosomal protein S23 (RPS23) gene (FC=1.521, unadjusted p=0.013306) were found to result in the largest expression change differences.
between subgroups. However, in female responders and female non-responders, the Family with Sequence Similarity 117 Member B (FAM117B) gene (FC=0.5257, unadjusted p=0.0048554) and the Golgin B1 (GOLGB1) gene (FC= -0.6536, unadjusted p=0.0003716) were differentially expressed, respectively and shown in Table 5.

**Table 3. Differentially expressed genes between male and female responders prior to Lithium pharmacotherapy with a log fold-change threshold of 0.5.**

| Genes downregulated in male lithium responders | Genes upregulated in female lithium responders |
|-----------------------------------------------|-----------------------------------------------|
| **Gene**                                      | **Gene**                                      |
| **Adjusted P-value**                          | **Adjusted P-value**                          |
| **P-value**                                   | **P-value**                                   |
| **Log fold change**                           | **Log fold change**                           |
| **Gene description**                          | **Gene description**                          |
| **Highest gene tissue expression**            | **Highest gene tissue expression**            |
| RBPM2                                        | HLA-H                                        |
| 1                                            | 1                                             |
| 0.00111                                      | 0.000996                                      |
| -1.351                                       | 1.602                                         |
| RNA Binding Protein with Multiple Splicing 2 | Major Histocompatibility Complex, Class I, H (pseudogene) |
| Heart, Urinary Bladder                       | Lymph Node, Bone Marrow                      |
| SIDT2                                        | RPS23                                        |
| 1                                            | 1                                             |
| 0.00932                                      | 0.00308                                       |
| -0.82                                        | 1.471                                         |
| S1D1 Transmembrane Family Member 2           | Ribosomal Protein S23                        |
| Stomach, Prostate                            | Ovary, Bone Marrow                            |
| CDH23                                        | FHL3                                         |
| 1                                            | 1                                             |
| 0.00388                                      | 0.000751                                      |
| -0.674                                       | 0.893                                         |
| Cadherin-Related 23                          | Four and a Half LIM Domains 3                 |
| Ovary, Prostate                              | Esophagus, Endometrium                       |
| LILRA5                                       | RPL10A                                       |
| 1                                            | 1                                             |
| 0.00359                                      | 0.00299                                       |
| -0.592                                       | 0.628                                         |
| Leukocyte Immunoglobulin Like Receptor A5    | Ribosomal Protein L10a                       |
| Appendix, Bone Marrow                        | Ovary, Bone Marrow                            |
| KIR2DS5                                      | **NBPF14**                                    |
| 1                                            | **0.0462**                                    |
| 0.00431                                      | 0.00000782                                    |
| -0.506                                       | 0.586                                         |
| Killer Cell Immunoglobulin Like Receptor, Two Ig Domains and Short Cytoplasmic Tail 5 | Neuroblastoma Breakpoint Family Member 14 |
| Testis, Adrenal                              | Skin, Ovary                                   |
| CHST7                                        | PSTPIP2                                      |
| 1                                            | 1                                             |
| 0.00812                                      | 0.000473                                      |
| 0.529                                        | 0.569                                         |
| Carbohydrate Sulfotransferase 7              | Proline-Serine-Threonine Phosphatase Interacting Protein 2 |
| Spleen, Fat                                  | Bone Marrow, Spleen                           |
| ABRACL                                       | FAM117B                                      |
| 1                                            | 1                                             |
| 0.00396                                      | 0.00949                                      |
| 0.505                                        | 0.556                                         |
| ABRA C-Terminal Like                         | Family with Sequence Similarity 117 Member B |
| Colon, Lymph Node                            | Testis, Adrenal                              |

**Notes:** **The NBPF14 gene reached the Benjamani-Hochberg adjusted p-value.**

**Discussion**

The purpose of this investigation was to define gender-specific transcriptome-level regulators of lithium treatment response prior to the initiation of lithium treatment. We first established the gender-relevant transcriptional control genes across all study-participant blood samples and specifically to male- and female-responders using a differential gene expression threshold of 0.5. We found this to be adequate and corroborated with similar studies that used a similar threshold for establishing gene transcription signatures (Jansen et al., 2014; Mayne et al., 2016). However, when comparing the male-responders to male non-responders, as well as, the female responders to female non-responders, we set an inclusion fold-change threshold to 0.3. This approach is not unusual, since it is already established that both large and subtle expression changes produce to significant biological and physiological processes (Wurmbach et al., 2002). Our analysis is both hypothesis-generating, and establishes a computational methodology that provides insight to the importance of subgroup analysis in genomic medicine, irrespective of patient sample-sizes. The end-goal of such analyses serves as a testing methodology for establishing gene screening panels to improve personalized medicine in vulnerable and high-risk patient populations. In these patient populations, it is often not feasible to wait for weeks to determine whether a prescribed medication will work and in some cases manic patients are neither able to fully comprehend and be objectively assessed using the CGI-BP-S (Spearing et al., 1997).

When reviewing the heat-map and dendrogram hierarchical cluster analysis patterns, specifically the numerous non-responders clinically-labeled and illustrated in Figure 4, they suggest that the underlying etiology resulting in clinical symptoms (e.g. mania) that led to the diagnosis of bipolar disorder may need re-classification. Further, the subsequent treatments may need to be tailored in data-driven computational psychiatry approaches. In Figure 4, for the females, the samples in the center cluster
Figure 3. Heat-map and dendrogram overview of the two-way unsupervised hierarchical cluster analysis of differentially expressed genes in male (n=3) and female (n=6) lithium responders after filtering out the top 250 differentially expressed genes found gender biased genes.

illustrates that a group of patients are clear non-responders while the patients clustered in the far-right are partial-responders, from a molecular perspective. The natural questions that arise are: (1) How to best convert the non- and partial-responders to treatment-responders? (2) Is a behavioral intervention, in this select group of patients, for whom lithium is not effective, the best answer because the symptoms maybe of a different etiology? If indeed the symptoms are of a different etiology (e.g. inflammatory), from the lithium treatment-responders, then other diagnostic (e.g. electrophysiological neuroimaging) tools may be warranted and corresponding most efficacious treatments sought.

When differentiating between male and female patients, we found that the Ribosomal Protein S4, Y-linked 1 (RPS4Y1, adjusted p-value=7.36E-47) male-linked gene and the X Inactive Specific Transcript (XIST, adjusted p-value=2.98E-36) female-linked gene were the most differentially expressed among genders, which is consistent with previously published studies (Guillén et al., 2014; Janssen et al., 2014; Mayne et al., 2016). The genes that are specific to male lithium responders, relative to female lithium responders, are RBPM52, SIT12, CDH23, LLRA5, and KIR2DS5. Using the same methodology, genes identifying female lithium responders, relative to male lithium responders, are HLA-H, RPS23, FHL3, RPL10A, NBPF14, PSTPIP2, FAM117B, CHST7, and ABRACL. The Neuroblastoma Breakpoint Family Member 14 (NBPF14, adjusted p-value=0.0462, Fold-change=0.586) achieved the Benjamani-Hochberg adjusted p-value of 0.0462, and has been reported to be associated with cortical neurogenesis (Suzuki et al., 2017).

Computational psychiatry, as advocated by the National Institute of Mental Health’s Research Domain Criteria (RDoC), may need data to drive the classification, diagnosis, and treatment response status, especially in patients with developmental delay, language difficulty, and condition of a potentially different etiology than traditionally taught (Clark et al., 2017; Eugene & Masiak, 2016). Ideally, in such cases, alternative FDA-approved mood stabilizers may be initially selected prior to any pharmacological intervention by simply using a blood test. Perhaps, a gene
| Gene          | Adjusted P-value | P-value | Log fold change | Gene description                                      | Highest gene tissue expression     |
|--------------|-----------------|---------|-----------------|-------------------------------------------------------|------------------------------------|
| **RBPMS2**   | 1               | 0.001358| -1.326          | RNA Binding Protein with Multiple Splicing 2           | Heart, Urinary Bladder             |
| **SVBP**     | 1               | 0.01366 | -0.76           | Small Vasohibin Binding Protein                       | Testis, Fat                        |
| **LILRA5**   | 1               | 0.011739| -0.714          | Leukocyte Immunoglobulin Like Receptor A5             | Appendix, Bone Marrow              |
| **CPA3**     | 1               | 0.008048| -0.592          | Carboxypeptidase A3                                    | Gall Bladder, Lung                  |
| **SLC45A3**  | 1               | 0.016508| -0.455          | Solute Carrier Family 45 member 3                      | Prostate, Stomach                   |
| **ZNF234**   | 1               | 0.003254| -0.41           | Zinc Finger Protein 234                                | Spleen, Thyroid                     |
| **DIDO1**    | 1               | 0.008232| -0.385          | Death Inducer-Obliterator 1                            | Ovary, Spleen                       |
| **TPP2**     | 1               | 0.013053| -0.385          | Tripeptidyl Peptidase 2                                | Testis, Thyroid                     |
| **KRT73**    | 1               | 0.007333| -0.373          | Keratin 73                                            | Skin, Lymph Nodes                   |
| **ZMYM3**    | 1               | 0.00363 | -0.372          | Zinc Finger MYM-type Containing 3                      | Ovary, Testis                       |
| **NOTCH2 NL**| 1               | 0.009657| -0.348          | Notch 2 N-terminal Like                                | Testis, Skin                        |
| **TIPRL**    | 1               | 0.007794| -0.34           | TOR Signaling Pathway Regulator                        | Endometrium, Brain                 |
| **CAMK1D**   | 1               | 0.005376| -0.333          | Calcium/Calmodulin dependent Protein Kinase ID         | Brain, Skin                         |
| **EFNA1**    | 1               | 0.00632 | -0.324          | Ephrin A1                                             | Placenta, Lung                      |

| Gene        | Adjusted P-value | P-value | Log fold change | Gene description                                      | Highest gene tissue expression     |
|-------------|-----------------|---------|-----------------|-------------------------------------------------------|------------------------------------|
| **RPS23**   | 1               | 0.013306| 1.521           | Ribosomal Protein S23                                  | Ovary, Bone Marrow                 |
| **IRF2BPL** | 1               | 0.010952| 1.005           | Interferon Regulatory Factor 2 Binding Protein Like   | --                                 |
| **HLA-C**   | 1               | 0.003461| 0.997           | Major Histocompatibility Complex, Class I, C          | Lung, Bone Marrow                   |
| **RGPD1**   | 1               | 0.001745| 0.76            | RANBP2-like and GRIP Domain Containing 1              | Testis, Liver                       |
| **ASGR2**   | 1               | 0.019947| 0.598           | Asialoglycoprotein Receptor 2                          | Liver, Gall Bladder                 |
| **LPAR1**   | 1               | 0.01374 | 0.453           | Lysophosphatidic Acid Receptor 1                      | Brain, Placenta                     |
| **RRN3P1**  | 1               | 0.017025| 0.42            | RRN3 homolog, RNA Polymerase I Transcription Factor Pseudogene 1 | Thyroid, Lymph Node               |
| **TOMM34**  | 1               | 0.016655| 0.416           | Translocase of Outer Mitochondrial Membrane 34        | Testis, Adrenal                     |
| **ACAD11**  | 1               | 0.015882| 0.405           | Acyl-CoA Dehydrogenase Family Member 11              | Kidney, Liver                       |
| **CEBPE**   | 1               | 0.00269 | 0.404           | CCAAT/enhancer Binding Protein Epsilon                | Bone Marrow, Small Intestine      |
| **CMIP**    | 1               | 0.017203| 0.394           | C-Maf Inducing Protein                                | Brain, Small Intestine             |
| **IGSF6**   | 1               | 0.011786| 0.38            | Immunoglobulin Superfamily Member 6                  | Spleen, Appendix                   |
| **HDHD2**   | 1               | 0.01764 | 0.361           | Haloacid Dehalogenase Like Hydrolase Domain Containing 2 | Brain, Thyroid                     |
| **LMO4**    | 1               | 0.012872| 0.359           | LIM Domain Only 4                                     | Brain, Stomach                      |
| **BACE2**   | 1               | 0.000711| 0.353           | Beta-site APP-Cleaving Enzyme 2                       | Stomach, Gall Bladder              |
| **TPP1**    | 1               | 0.00061 | 0.341           | Tripeptidyl Peptidase 1                                | Spleen, Appendix                   |
| **GALNS**   | 1               | 0.007613| 0.341           | Galactosamine (N-acetyl)-6-Sulfatase                   | Bone Marrow, Testis                |
| **SYNM**    | 1               | 0.019042| 0.322           | Synemin                                                | Esophagus, Prostate                |

Table 4. Differentially expressed genes between Male Responders and Male Non-Responders at baseline with a log fold-change threshold of 0.3.

expression screening panel at baseline, prior to the initiation of lithium and/or other FDA-approved mood stabilizer, may be better in high-risk patient populations.

These findings suggest that when implementing genomic medicine, clinical research teams should move beyond the single-gene approach when screening for treatment responders or non-responders. This approach is currently the standard when screening for patient toxicity at standard doses in poor or ultra-rapid metabolizers; however, as more transcriptional factors are discovered that regulate the cytochrome (CYP) P-450 system of genes, multi-gene pharmacokinetic panels are inevitable and may be included in future Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines. Next, medical management of patients with mania and psychosis either with pharmacotherapy and/or behavioral intervention should be tailored to biological...
Table 5. Differentially expressed genes between Female Responders and Female Non-Responders at baseline with a log fold-change threshold of 0.3.

| Genes          | Adjusted P-value | P-value     | Log fold change | Gene Description                          | Highest gene tissue expression |
|----------------|------------------|-------------|-----------------|-------------------------------------------|-------------------------------|
| **Upregulated gene in female lithium responders** |                  |             |                 |                                           |                               |
| FAM117B        | 0.998            | 0.0048554   | 0.5257          | Family with Sequence Similarity 117 Member B | Testis, Adrenal               |
| STAMBPL1       | 0.998            | 0.0074433   | 0.39            | STAM Binding Protein Like 1               | Adrenal, Testis               |
| CD248          | 0.998            | 0.0038199   | 0.3626          | CD248 Molecule                            |                               |
| IFIH1          | 0.998            | 0.0075822   | 0.3453          | Interferon Induced with Helicase C domain 1| Spleen, Appendix              |
| GPR160         | 0.998            | 0.0071723   | 0.3394          | G Protein-coupled Receptor 160            | Small Intestine, Duodenum     |
| STAP1          | 0.998            | 0.0053096   | 0.3222          | Signal Transducing Adaptor Family Member 1| Lymph Node, Appendix          |
| YEATS4         | 0.998            | 0.0089003   | 0.3103          | YEATS Domain Containing 4                 | Testis, Bone Marrow          |
| CD83           | 0.998            | 0.0004367   | 0.3014          | CD83 Molecule                             | Bone Marrow, Lymph Node       |
| TMOD2          | 0.998            | 0.0081514   | 0.3012          | Tropomodulin 2                            | Brain, Appendix               |
| **Downregulated gene in female lithium non-responders** |                  |             |                 |                                           |                               |
| GOLGB1         | 0.998            | 0.0003716   | -0.6536         | Golgin B1                                 |                               |
| RASA4CP        | 0.998            | 0.0030349   | -0.4554         | RAS p21 Protein Activator 4C, Pseudogene  | Spleen, Endometrium           |
| NACC2          | 0.998            | 0.0061286   | -0.3803         | NACC Family Member 2                      | Brain, Fat                    |
| EDARADD        | 0.998            | 0.0021425   | -0.3553         | EDAR Associated Death Domain              | Urinary Bladder, Kidney       |
| ZNF573         | 0.998            | 0.0058465   | -0.3463         | Zinc Finger Protein 573                   | Thyroid, Spleen               |
| ALDH2          | 0.998            | 0.0031872   | -0.335          | Aldehyde Dehydrogenase 2 Family (mitochondrial) | Fat, Liver                  |
| TAPBPL         | 0.998            | 0.0032596   | -0.3206         | TAP Binding Protein Like                   | Duodenum, Small Intestine     |

Gender due to known neuronal circuitry differences in age-matched patients with psychosis (Eugene et al., 2015). Further, as a result of lithium not being hepatically metabolized, but rather transported and renally excreted, as well as, the known myriad drug-drug interactions, patient dose selection may benefit from clinical pharmacometrics modeling by board-certified/eligible pharmacologists (Perera et al., 2014; Zetin et al., 1986). This approach may be implemented to ensure drug pharmacokinetic safety.

The limitations of our analysis and in most genetic studies are understandably due to multiple-comparison p-value adjustments and patient sample size (Dudoit et al., 2003). The fundamental aims of our research questions were designed to answer biological questions of gender and clinical response to lithium and not meant to be driven exclusively by multiple comparisons adjusted p-values. This approach has led to various successes in genomic medicine, specifically, in genome-wide association studies; however, understandably, the limitations are thoroughly acknowledged. In reference to patient sample sizes, 9 out of the 28 patients who received lithium and optimal therapy were classified as lithium treatment responders. Further, 30% of men and 33% of women, who were treated with lithium, were found to be responders at the respective gender categories (Beech et al., 2014). However, the strengths of our findings are in the gender-gene screening ability for lithium treatment-responders in the general population of 60 patients at baseline, minus the tested responder group. Opportunities exist for prospective clinical trials and application of the methods outlined in this text for other therapeutic agents across several medical specialties.
Conclusion
We explored the Lithium Treatment-Moderate dose Use Study clinical trial gene expression data with the aim of identifying gender-specific transcriptome-level regulators of lithium treatment response. Using machine learning, we successfully developed a pre-treatment gender- and gene-expression-specific predictive model selective for lithium responders with an ROC AUC of 0.92 for men and an ROC AUC of 1 for women. Further, by using well-established Bayesian statistical methods, to identify differentially expressed genes and then machine learning, we discovered 5-genes selective for men and 9-genes that are selective for women that will inform the physicians and clinical staff of whether the patient will respond to lithium prior to being prescribed the drug. With the small number of patient responders from the clinical trial, our results should be confirmed. Lastly, in an overall context, our results suggest that the methodology used in this analysis may be extended to other therapeutic drug classes and provides insight to the gender-based gene transcriptome differences influencing lithium pharmacodynamics.

Data availability
Data used in this study are available from https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE45484

Competing interests
No competing interests were disclosed.

Grant information
The author(s) declared that no grants were involved in supporting this work.

Acknowledgements
The authors gratefully acknowledge the patients in the original clinical trial, the medical staff, and the NCBI GEO database accession GSE4548.
Supplementary material

Supplementary File 1: Supplementary methods.

Click here to access the data.

References

Beech RD, Leflert JJ, Lin A, et al.: Gene-expression differences in peripheral blood between lithium responders and non-responders in the Lithium Treatment-Moderate dose Use Study (LTMUS). Pharmacogenomics J. 2014; 14(2): 182–91. PubMed Abstract | Publisher Full Text

Clark LA, Cuthbert B, Lewis-Fernández R, et al.: Three Approaches to Understanding and Classifying Mental Disorder: ICD-11, DSM-5, and the National Institute of Mental Health’s Research Domain Criteria (RDoC). Psychol Sci Public Interest. 2017; 18(2): 72–145. PubMed Abstract | Publisher Full Text

Dudoit S, Shaffer JP, Boldrick JC: Multiple Hypothesis Testing in Microarray Experiments. Statist Sci. 2003; 18(1): 71–103. Publisher Full Text

Eugene AR, Masiak J: Identifying Treatment Response of Sertraline in a Teenager with Selective Mutism Using Electrophysiological Neuroimaging. Int J Clin Pharmacol Toxicol. 2016; 5(4): 216–19. PubMed Abstract | Free Full Text

Eugene AR, Masiak J, Kapica J, et al.: Electrophysiological Neuroimaging Using sLORETA Comparing 22 Age Matched Male and Female Schizophrenia Patients. Hosp Chron. 2015; 10(2): 91–98. PubMed Abstract | Free Full Text

Guilén IA, Fernández JR, Palenzuela DO, et al.: Analysis of Gene Expression Profile for Gender in Human Blood Samples. International Journal of Innovation and Applied Studies. 2014; 7(1): 328–42. Reference Source

Hayes JF, Pitman A, Marston L, et al.: Self-harm, Unintentional Injury, and Suicide in Bipolar Disorder During Maintenance Mood Stabilizer Treatment: A UK Population-Based Electronic Health Records Study. JAMA Psychiatry. 2016; 73(6): 630–7. PubMed Abstract | Publisher Full Text

Hemke C, Baumann P, Bergmann N, et al.: AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011. Pharmacopsychiatry. 2011; 44(6): 195–235. PubMed Abstract | Publisher Full Text

Jansen R, Balista S, Brooks AJ, et al.: Sex differences in the human peripheral blood transcriptome. BMC Genomics. 2014; 15(1): 33. PubMed Abstract | Publisher Full Text | Publisher Full Text

Jemain DM, Crismon ML, Martin ES 3rd: Population pharmacokinetics of lithium. Clin Pharm. 1991; 10(5): 376–81. PubMed Abstract

Labonté B, Engmann O, Purushothaman I, et al.: Sex-specific transcriptional signatures in human depression. Nat Med. 2017; 23(9): 1102–11. PubMed Abstract | Publisher Full Text | Free Full Text

Landersdorfer CB, Findling RL, Frazer JA, et al.: Lithium in Paediatric Patients with Bipolar Disorder: Implications for Selection of Dosage Regimens via Population Pharmacokinetics/Pharmacodynamics. Clin Pharmacokinet. 2017; 56(1): 71–90. PubMed Abstract | Publisher Full Text

Lobeck F, Nelson MV, Evans RL, et al.: Evaluation of Four Methods for Predicting Lithium Dosage. Clin Pharm. 1987; 6(3): 230–33. PubMed Abstract

Mayne BT, Bianco-Miotto T, Buckberry S, et al.: Large Scale Gene Expression Meta-Analysis Reveals Tissue-Specific, Sex-Biased Gene Expression in Humans. Front Genet. 2016; 7: 183. PubMed Abstract | Publisher Full Text | Free Full Text

Perera V, Bies RR, Mo G, et al.: Optimal sampling of antipsychotic medicines: a pharmacometric approach for clinical practice. Br J Clin Pharmacol. 2014; 78(4): 803–814. PubMed Abstract | Publisher Full Text | Free Full Text

Ritchie ME, Phipson B, Wu D, et al.: Limma Powers Differential Expression Analyses for RNA-Sequencing and Microarray Studies. Nucleic Acids Res. 2015; 43(7): e47. PubMed Abstract | Publisher Full Text | Free Full Text

Spearling MK, Post RM, Leverich GS, et al.: Modification of the Clinical Global Impressions (CGI) Scale for Use in Bipolar Illness (BP): The CGI-BP. Psychiatry Res. 1997; 73(3): 159–71. PubMed Abstract | Publisher Full Text

Suzuki IK, Gaczker D, Van Heurck R, et al.: Hominin-Specific NOTCH2 Paralogs Expand Human Cortical Neurogenesis through Regulation of Delta/Notch Interactions. bioRxiv. Cold Spring Harbor Laboratory, 2017; 221358. Publisher Full Text

Team R: R Development Core Team. R: A Language and Environment for Statistical Computing. 2013. Reference Source

Viguer a CA, Tondo L, Baldessarini RJ: Sex differences in response to lithium treatment. Am J Psychiatry. 2000; 157(9): 1509–11. PubMed Abstract | Publisher Full Text

Wurmback E, González-Maeso J, Yuen T, et al.: Validated genomic approach to study differentially expressed genes in complex tissues. Neurochem Res. 2002; 27(10): 1027–33. PubMed Abstract | Publisher Full Text

Zetin M, Garber D, De Antonio M, et al.: Prediction of lithium dose: a mathematical alternative to the test-dose method. J Clin Psychiatry. 1986; 47(4): 175–78. PubMed Abstract
Open Peer Review

Current Peer Review Status:   ?

Version 1

Reviewer Report 21 May 2018

https://doi.org/10.5256/f1000research.15730.r33941

© 2018 Ho M. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Ming-Fen Ho
Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA

The authors demonstrated that sex-differences gene expression might contribute to lithium treatment response using microarray expression data.

Major comments:
1. A samples size of 60 might be too small to determine the sex effects. Can the sample size n=60 provide adequate power for data interpretation, especially separated men and women for study sex-effect on gene expression?

2. The authors stated that their predictive model for lithium responders with an ROC AUC 0.92 for men, and 1 for women. If the prediction accuracy is so significant, what are the potential biological mechanisms beyond these genes? More discussion regarding the biology of those genes should be included in the paper. Once again, if the prediction accuracy is so significant, it is needed a replication study using different data sets? In summary, the authors claimed the prediction model with very high accuracy; it should be included either functional validation of those genes or a replication study population.

Specific comments:
1. Methods - study design, it might be better to use a flow chart to demonstrate the study design.

2. Methods - study design, please clarify the rationale of filtering out “250” genes.

3. Table 1 shows total study population n=60, but figure 1 legend shows male: n=41, female: n=39?

4. Figure 2: please elaborate the data presented in Figure 2. The key results for each of the four panels should be summarized in Results.
5. Table 2 and Table 4, the log FC threshold of 0.5 or 0.3 might be too low. The changes in gene expression are very subtle in Table 4.

6. Table 2, are there any gene up-regulated in males? downregulated in females?

7. Limitations of the study should be addressed in Discussion.

**Is the work clearly and accurately presented and does it cite the current literature?**
Partly

**Is the study design appropriate and is the work technically sound?**
Partly

**Are sufficient details of methods and analysis provided to allow replication by others?**
Partly

**If applicable, is the statistical analysis and its interpretation appropriate?**
Partly

**Are all the source data underlying the results available to ensure full reproducibility?**
Partly

**Are the conclusions drawn adequately supported by the results?**
Partly

**Competing Interests:** No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

**Author Response 21 May 2018**

**Andy Eugene**

**Major Comment Responses:**

**Response 1:**
This point is well noted; however, it is important to realize that our gender-effects of gene expression is consistent with other studies noted within the paper and shown below:

Jansen, Rick, et al. "Sex differences in the human peripheral blood transcriptome." *BMC genomics* 15.1 (2014): 33.

Mayne, Benjamin T., et al. "Large scale gene expression meta-analysis reveals tissue-specific, sex-biased gene expression in humans." *Frontiers in genetics* 7 (2016): 183. Further, our gender-specific results met the Benjamini-Hochberg multiple comparisons criteria adjustment due to multiple comparisons.
Comment Response 2:
We welcome and thank the reviewer’s comments on the biological mechanisms beyond these genes. Clearly, it is well noted and cited in the paper that in clinical practice there is a wide inter-individual variability in the treatment and response to treatments of bipolar disorder. Moreover, these patients were not treated with lithium monotherapy, alone, and therefore further insight into the biological mechanisms were left out due to these patients were treated with an “Optimal Therapy” that includes a variety of other FDA-approved mood stabilizers.

In reference to the comment regarding the prediction accuracy, we agree that the study may warrant functional validation in a laboratory; however, it is beyond the scope of our computational psychiatry study and we will leave the functional genomics characterization of the genes to investigators seeking to pursue the findings from our results.

Competing Interests: No competing interests were disclosed.

Author Response 21 May 2018
Andy Eugene

Specific Comment Responses:
We thank you for your specific comments and have addressed several of the pertinent points in your review. For all differentially expressed results reported throughout tables within the manuscript, we changed the wording from genes up-regulated or down-regulated in males or females to a clearer description statement that genes-associated with males or females. However, we thought not necessary to include an extra figure, but rather encourage the reader to (1) review the study design section within the methods to better understand the computational approach used in our analysis and (2) read the systematic tabular reporting of the results in the manuscript text as well to understand that study approach.

For the caption in Figure 1, we thank you for the comment and have updated the sample sizes for males and female patients. The updated Figure 1 text reads: Males (n=20; with 40 pre- and post-treatment samples) and Females (n=40; with 80 pre- and post-treatment samples).

The comments regarding: (1) the fold-change of 0.5 and 0.3 being subtle and (2) the study limitations, are already specifically addressed within the original version of the manuscript. Again, it is well established and referenced within the text that small changes in gene expression have already been reported to result in major functional outcomes in human physiology.

We will update the variable importance illustration shown in Figure 2 and that will be added to the updated version of the manuscript.
Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com